Standex (SXI) Q3 2026 earnings review
Organic Growth and Deleveraging Drive a Strong Quarter
Standex delivered a robust Q3 FY26, fueled by a 6.5% organic revenue increase and a highly successful deleveraging effort. Adjusted EPS grew 13.5% to $2.21, beating expectations as the Electronics and Aerospace & Defense segments fired on all cylinders. The company completed the divestiture of Federal Industries for $70M, simplifying its portfolio into four segments and generating cash that helped crush its net leverage ratio down to 1.9x (from 3.0x a year ago). While overall margins expanded slightly, management guided for slight YoY margin contraction in Q4 due to growth investments, signaling a reinvestment phase rather than structural weakness.
🐂 Bull Case
Electronics delivered 6.8% organic growth with a stellar 1.14 book-to-bill ratio, while Aerospace & Defense organic revenue surged 20.8%. Demand in electrical grid and space markets remains highly resilient.
Net leverage plummeted to 1.9x following the Federal Industries divestiture and $62M in Q3 debt paydown. This creates massive optionality for future M&A or shareholder returns.
🐻 Bear Case
Q4 Adjusted Operating Margin is guided slightly lower YoY as growth investments, higher medical costs, and variable compensation offset volume leverage.
The Scientific segment continues to shrink (-1.7% organically) due to macro-level NIH funding cuts impacting academic and research institutions.
⚖️ Verdict: 🟢
Bullish. Standex is demonstrating excellent portfolio management. Shedding the Federal Industries business allows management to focus on high-growth, high-margin end markets, and the rapid deleveraging derisks the balance sheet.
Key Themes
Aerospace & Defense Scaling Rapidly
Accelerating. The newly renamed Aerospace & Defense segment (formerly Engineering Technologies) grew revenue 33.7% YoY, driven by a 20.8% organic surge and the McStarlite acquisition. Increased project activity in the commercialization of space is translating directly into top-line acceleration.
Portfolio Simplification and Rapid Deleveraging
Stable. The $70M divestiture of Federal Industries cleanly exits a non-core business and consolidates operations into four streamlined segments. Standex used the cash to aggressively pay down $62M of debt, dropping the net debt-to-EBITDA ratio to 1.9x—down from 3.0x a year ago and well below the 2.8x seen in early FY25. This creates significant balance sheet powder.
New Products & Fast Growth Markets
Stable. Management's R&D engine continues to deliver. New product sales contributed 8% to Q3 growth, and the company plans to release >15 new products in FY26 to drive ~300bps of incremental growth. Meanwhile, sales into 'Fast Growth' markets hit ~$69M in Q3 and are on track for ~$270M in FY26 (up ~45% YoY).
Q4 Margin Compression
Reversing. After multiple quarters of margin expansion, Q4 Adjusted Operating Margin is expected to be slightly lower YoY. The company cites growth investments, medical costs, and variable compensation outstripping productivity gains. While likely transient, it interrupts a strong streak of margin accretion.
Scientific Segment Suffers Macro Policy Headwinds
Stable. The Scientific segment remains the odd man out, posting a 1.7% organic revenue decline. Management explicitly linked this to lower demand from academic and research institutions impacted by U.S. National Institutes of Health (NIH) funding cuts. Until this macro policy headwind resolves, the segment will drag on consolidated growth.
Other KPIs
A highly bullish forward indicator. Orders of ~$136 million comfortably exceeded revenue of $119.7 million. This metric has expanded from 1.06 in 26Q1, indicating that demand in the electrical grid and test/measurement markets is actively accelerating.
Up 81.5% YoY from $3.5M in 25Q3. The improvement demonstrates better working capital management despite elevated capital expenditure requirements and growth investments.
Massively distorted by a $56.8 million gain on the sale of the Federal Industries business. Adjusted operating margin of 19.7% provides the true operational picture, showing a modest 30 bps YoY expansion.
Guidance
Accelerating sequentially. Driven by mid-to-high single digit organic growth from fast growth end markets, partially offset by the absence of Federal Industries revenue.
Reversing. Expected to drop compared to the prior year as the company absorbs higher medical and variable compensation costs alongside strategic growth investments.
Stable. The company previously guided to >$110 million but adjusted this to ~$100 million to account for the Federal Industries divestiture. The underlying organic momentum remains intact.
Stable. Roughly in line with the $28.3 million spent in FY25, indicating normalized reinvestment rates post-acquisitions.
Key Questions
Capital Allocation Post-Deleveraging
With net leverage down to 1.9x and the Federal Industries cash secured, does the M&A pipeline dictate keeping powder dry, or will we see a resumption of aggressive share repurchases?
Margin Investment Duration
Q4 operating margins will be slightly lower YoY due to growth investments. Should we view this as a one-quarter reset, or a structurally higher OPEX run-rate heading into FY27?
Scientific Segment Strategy
Given the ongoing structural headwinds from NIH funding cuts, does the Scientific segment still fit the long-term portfolio profile now that the company is aggressively simplifying operations?